San Carlos, CA, United States
San Carlos, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | April 20, 2017
Site: marketersmedia.com

— Intracranial pressure (ICP) monitoring is used in treating patients suffering from severe brain injury. In this process a sensor device is been used and placed inside the head to measure the pressure inside the skull and send it to a recording device, Intracranial pressure monitoring can be performed in following three ways, Intraventricular Catheter: is the most accurate method. In this method Intraventricular Catheter is inserted through a hole in the skull and place in the lateral ventricle. Subdural Screw: In this method hollow screw is placed in the skull. It is placed between a membrane that protects the spinal cord and the brain. Epidural Sensor: The Epidural Sensor is placed between the skull and dural tissue by drilling a hole in the skull Intracranial pressure (ICP) monitoring is mainly used in hospitals for patients suffering from brain injury, meningitis and intracerebral hemorrhage. There are multiple ICP products that have been used in hospitals such as Surgical Instruments, IAP-Monitoring, Hydrocephalus, CSF drainage and many more. The microtransducers and ventriculostomy is included invasive method whereas tympanic membrane displacement, transcranial Doppler, CT scan/ MRI, optic nerve sheath diameter, and fundoscopy is included in noninvasive methods. The major growth drivers of Intracranial pressure monitoring market is increasing global incidence and prevalence of neurological disorders, rising awareness about neurodegenerative diseases, technological advancements in brain monitoring devices and growing incidence of traumatic brain injuries. The shortage of trained professionals, high cost of complex brain monitoring devices, unfavorable reimbursement policies and concerns regarding the accuracy of diagnostic devices are the major restraints of ICP market. ICP monitoring market segmentation can be done by method, market, Instrument, applications and End-users. ICP monitoring market by Method: Invasive and Non- invasive, ICP monitoring market by Market: external ventricular drain, fiber optic monitor, strain gauge transducer and air-pouch device market. ICP monitoring market by Instrument: Devices and accessories, ICP monitoring market by Applications: Traumatic Brain Injury, Intracerebral Hemorrhage, Meningitis, and Subarachnoid Hemorrhage, ICP monitoring market by End-users: Trauma centers, hospitals, clinics and diagnostic laboratories. North America: North America dominates the ICP monitoring market due to large number of traumatic brain injury cases. Also, the growing number of Traumatic Brain Injury (TBI) cases and need for continuous ICP monitoring of the patients suffering from TBI are the factors driving the intracranial pressure monitoring devices market in the U.S. Additionally, Increasing Awareness About Neurodegenerative Diseases and Rising Government Initiatives are also propelling the market towards growth. North America market is broadly classified into product and applications. Based on product the market is segmented into Extra Ventricular Drainage (EVD) and ICP Monitors whereas based on applications market is segmented into Traumatic Brain Injury, Intracerebral Hemorrhage, Meningitis and Others. Asia: Asian countries is showing highest growth rate in the upcoming years. The growing neurological complications and government initiatives for raising the awareness in people towards the neurological complications and its treatment is driving the ICP Monitoring market. Japan, China, and India are relied upon to be among the highest developing markets for the intracranial pressure devices because of different ventures and research offices. Intracranial pressure (ICP) monitoring market major players: • Natus Medical Inc. (U.S.) • Nihon Kohden Corporation (Japan) • Philips Healthcare (Netherlands) • GE Healthcare (U.K.) • Siemens Healthcare (Germany) • Compumedics Ltd. (Australia) • Electrical Geodesics Incorporated (U.S.) • Medtronic Inc. (Ireland) • CAS Medical Systems, Inc. (U.S.) • dvanced Brain Monitoring (U.S.) Every report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report also gives a broad study of the different market segments and regions. For more information, please visit https://www.marketresearchfuture.com/reports/intracranial-pressure-monitoring-market


Receive press releases from IQ4I Research & Consultancy Pvt. Ltd.: By Email IQ4I Research & Consultancy Published a New Report on "Brain Monitoring Devices Global Market – Forecast to 2023" Brain monitoring devices aid in understand the activity of brain and explore structure and functions. Increasing incidence and prevalence neurological diseases, rising awareness, technological advancements/innovations are driving the market growth. Boston, MA, April 25, 2017 --( Brain monitoring devices market is growing at a steady rate, as estimated by IQ4I Research the market is expected to reach $10.01billion by 2023. The major factors driving the brain monitoring device market includes growing incidence and prevalence of neurological disorders, rising awareness about neurodegenerative disorders, growing healthcare spending and technological advancements/innovations offering wider scope of applications for brain monitoring. However, some of the factors like shortage of trained professionals, high cost of complex devices, stringent regulations and unfavorable reimbursement policies may hinder the growth of global brain monitoring device market. The brain monitoring devices global market is segmented based on their products, applications, end users and geography. Among products, sleep monitoring devices holds the largest market share because of the advancements in portable sleep devices technologies and growing incidence of obstructive sleep apnea. Sleep monitoring devices is expected to grow at the single digit mid-CAGR. The global brain monitoring devices application segment is classified into neurodegenerative disorders, brain tumor, psychiatric disorders, sleep disorders and other applications. Neurodegenerative diseases are characterized by progressive loss of neurons in the central nervous system and Epilepsy, Parkinson's disease (PD), Huntington’s disease falls under this category. In 2016, the market was estimated to be dominated by neurodegenerative disorders. The large share of this segment can be attributed to the growing incidence of Traumatic Brain Injuries (TBIs) globally owing to various factors like, increasing occurrence of falls, blunt trauma and motor vehicle crashes among other causes of TBIs and along with the increasing aging population. Geographically, the bran monitoring devices market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America region held the largest market share within that United States accounted for the largest share this growth is driven due to its high acceptance of advanced technologies and sophisticated universal treatment facilities. Asia- Pacific region is the fastest growing region due to its increase in healthcare spending and advancements in healthcare facilities, the easy access to advanced healthcare technology. The global brain monitoring devices market is fragmented where key players like GE Healthcare (U.S.), Philips N.V. (Netherland), Siemens Healthineers (Germany), Medtronic (Ireland) and Natus Medical Inc. (U.S.) holding a major share in 2016. The protection of intellectual property rights plays a very important role as a long term strategy for survival of the company and to maintain a competitive advantage. According to IQ4I Analysis, Advanced Brain Monitoring filed the largest number of PCT applications followed by Siemens Healthineers and Philips N.V. at World Intellectual Property Organization (WIPO). Some of the prominent players in brain monitoring device market include Advanced Brain Monitoring (U.S.), Cadwell Laboratories (U.S.), CAS Medicals Inc. (U.S), Compumedics Limited (Australia), Electrical Geodesics Incorporated (U.S.), Elekta AB (Sweden), GE Healthcare (U.S.), Integra Lifesciences (U.S.), Koninklijke Philips N.V. (Netherland), Masimo corporation (U.S.), Medtronic (Ireland), Natus Medical Inc.(U.S.), Nihon Kohden Corporation (Japan) and Siemens Healthineers (Germany). Boston, MA, April 25, 2017 --( PR.com )-- Brain monitoring devices are used to monitor and diagnose the neurological conditions by exploring the structure and functions of the brain in patients. These devices provide the information of the brain and greater understanding of neurological problems, with possible new treatments. Among brain monitoring devices CT and MRI are the conventional devices which are being used for the structural diagnosis of the brain like tumour, head injury etc., whereas EEG, MEG, TCD, oximeters and ICP monitors are the recent techniques used for the functional imaging of the brain. EEG measures the electrical activity generated by the various cortical layers of the brain whereas, MEG capture the magnetic fields generated by neural activity within the brain. Similarly, TCD measures the velocity of the blood flow through the brain’s blood vessels, oximeters are used to measure the regional cerebral oxygen saturation with in the brain and ICP monitors monitor the intracranial pressure within the skull while treating severe traumatic brain injury in patients. In addition to all these devices, sleep monitoring devices which occupies major share in the brain monitoring devices global market, are being used to understand the person’s sleep physiology and track sleep with the aim of finding patterns and correlations with person’s behaviours.Brain monitoring devices market is growing at a steady rate, as estimated by IQ4I Research the market is expected to reach $10.01billion by 2023. The major factors driving the brain monitoring device market includes growing incidence and prevalence of neurological disorders, rising awareness about neurodegenerative disorders, growing healthcare spending and technological advancements/innovations offering wider scope of applications for brain monitoring. However, some of the factors like shortage of trained professionals, high cost of complex devices, stringent regulations and unfavorable reimbursement policies may hinder the growth of global brain monitoring device market.The brain monitoring devices global market is segmented based on their products, applications, end users and geography. Among products, sleep monitoring devices holds the largest market share because of the advancements in portable sleep devices technologies and growing incidence of obstructive sleep apnea. Sleep monitoring devices is expected to grow at the single digit mid-CAGR.The global brain monitoring devices application segment is classified into neurodegenerative disorders, brain tumor, psychiatric disorders, sleep disorders and other applications. Neurodegenerative diseases are characterized by progressive loss of neurons in the central nervous system and Epilepsy, Parkinson's disease (PD), Huntington’s disease falls under this category. In 2016, the market was estimated to be dominated by neurodegenerative disorders. The large share of this segment can be attributed to the growing incidence of Traumatic Brain Injuries (TBIs) globally owing to various factors like, increasing occurrence of falls, blunt trauma and motor vehicle crashes among other causes of TBIs and along with the increasing aging population.Geographically, the bran monitoring devices market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America region held the largest market share within that United States accounted for the largest share this growth is driven due to its high acceptance of advanced technologies and sophisticated universal treatment facilities. Asia- Pacific region is the fastest growing region due to its increase in healthcare spending and advancements in healthcare facilities, the easy access to advanced healthcare technology.The global brain monitoring devices market is fragmented where key players like GE Healthcare (U.S.), Philips N.V. (Netherland), Siemens Healthineers (Germany), Medtronic (Ireland) and Natus Medical Inc. (U.S.) holding a major share in 2016. The protection of intellectual property rights plays a very important role as a long term strategy for survival of the company and to maintain a competitive advantage. According to IQ4I Analysis, Advanced Brain Monitoring filed the largest number of PCT applications followed by Siemens Healthineers and Philips N.V. at World Intellectual Property Organization (WIPO).Some of the prominent players in brain monitoring device market include Advanced Brain Monitoring (U.S.), Cadwell Laboratories (U.S.), CAS Medicals Inc. (U.S), Compumedics Limited (Australia), Electrical Geodesics Incorporated (U.S.), Elekta AB (Sweden), GE Healthcare (U.S.), Integra Lifesciences (U.S.), Koninklijke Philips N.V. (Netherland), Masimo corporation (U.S.), Medtronic (Ireland), Natus Medical Inc.(U.S.), Nihon Kohden Corporation (Japan) and Siemens Healthineers (Germany). Click here to view the list of recent Press Releases from IQ4I Research & Consultancy Pvt. Ltd.


(PRLEAP.COM)– According to a new series of reports on the Japan patient monitoring device market by iData Research ( www.idataresearch.com ), reimbursement cuts and consolidation within the industry has reduced the total market opportunity, resulting in low market growth and declining average selling prices (ASP). Despite growing demand for quality patient monitoring solutions, some hospitals in Japan cannot afford high-cost monitoring platforms due to budget constraints."A prevailing trend across the region relates to the adoption of less-invasive, more accessible, patient-centric monitoring device configurations," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "Emphasis is now being placed on patient comfort and mobility across lower-acuity care settings, wherein gaps in monitoring are further being filled with portable solutions."Increased competitiveness within the total patient monitoring market has also had a negative impact on market growth. The entry of low cost foreign competition in Japan has been especially disruptive because tenders are frequently won on the basis of cost over quality. However, the long-term prospects remain positive as demand for increased levels of monitoring will enable unit sales growth to outpace pricing pressure. This positive outlook combined with fast growing segments such as telehealth and wireless ambulatory telemetry monitoring will facilitate accelerated market growth in the region over the next several years.Nihon Kohden is the leading competitor in the patient monitoring device and equipment market in Japan. They are the market leader in the multi-parameter vital sign monitoring market, the wireless ambulatory telemetry monitor market, the electromyography (EMG) market, the electroencephalogram (EEG) market and the fetal and neonatal monitoring market. Their extensive product line includes the CNS-9701™ and I™ for central monitoring, the I™ product line of bedside monitors, I™, AirEEG WEE-1000™, and Neurofax™ EEG product lines. Their strength in Japan can be attributed to their strong local sales force and good relationships with hospitals.Fukuda Denshi is the second leading competitor in the Japanese patient monitoring market. Having been involved in the medical instrument market for over 75 years, this Japanese company has acquired substantial market share in the vital signs monitoring, wireless ambulatory telemetry monitoring, and pulse oximetry monitoring markets. Fukuda Denshi offers monitors in the high-, mid- and low-acuity segments with their Dynascope™ product line. Their strength can be attributed to their strong presence in Japan, where their relationship with local customers and their reputation as a market leader in the electrocardiograph (ECG) market contributed to their strong position. Additional competitors in the Japan patient monitoring market include Philips Healthcare, Medtronic, Omron Healthcare, Natus Medical, Masimo and GE Healthcare among others.More on the patient monitoring device market in Japan can be found in a series of reports published by iData Research entitled the Japan Market Report Suite for Patient Monitoring Equipment . The suite covers reports on the following markets: multi-parameter vital signs monitoring, wireless ambulatory telemetry monitoring, electromyogram monitoring, electroencephalogram monitoring, fetal and neonatal monitoring, pulse oximetry.The iData report series on patient monitoring devices covers the U.S., China, Australia, India, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about patient monitoring device market data, register online or email us at info@idataresearch.net for a Japan Market Report Suite for Patient Monitoring Equipment brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


SAN DIEGO, CA / ACCESSWIRE / April 25, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending on behalf of certain purchasers of NASDAQ: BABY shares against Natus Medical Inc. over alleged Violations of Securities Laws. Investors who purchased shares Natus Medical Inc (NASDAQ: BABY) prior to September 2015 and continue to hold any NASDAQ: BABY shares have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On October 16, 2015, Natus Medical Inc. announced that its Argentinian subsidiary had entered into a three-year supply contract with the Ministry of Health of Venezuela (the "Ministry of Health") pursuant to which the Company would receive $232.5 million, including $69 million in prepayments "expected" during the first quarter of 2016 (the "Supply Contract"). On October 21, 2015, Natus Medical Inc. issued a release in which it increased its revenue and earnings guidance for its fiscal year ending December 31, 2015. The plaintiff claims that the defendants issued false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects, including, among other things, that the Venezuelan government had failed to make tens of millions of dollars in prepayments to Natus Medical Inc, which were required to have been paid beginning in October 2015, that Natus Medical Inc. had no means to effectively enforce its rights under the Supply Contract, as Venezuela was the exclusive forum for dispute resolution, that Natus Medical Inc.'s receipt of revenues pursuant to the Supply Contract was contingent on the outcome of Venezuelan elections, and that as a result of the foregoing, Natus was not on track to achieve the increased guidance provided by defendants and such guidance lacked a reasonable basis. On January 11, 2016, Natus Medical Inc revealed that it expected to fall short of its fourth quarter and fiscal year 2015 guidance. Natus Medical Inc. also disclosed that "[t]he guidance provided by the Company in October for the fourth quarter of 2015 included expected revenue of approximately $4 million under the new Venezuelan Ministry of Health contract," but "[t]he Company was not able to ship product on the anticipated schedule because the prepayment under the contract was delayed." On February 29, 2016, Natus Medical Inc. filed its Annual Report on Form 10-K for fiscal year 2015 with the SEC, which disclosed that elections in Venezuela and Argentina and Venezuela's "highly inflationary economy and recessionary economic conditions" "may impact the likelihood of the Venezuelan Ministry of Health's following through with orders under the agreement, and [Natus's Argentinian subsidiary] ha[d] not yet received any prepayments under the agreement and no products or services ha[d] been shipped or provided." The Company attached a copy of the Supply Contract to the 10-K, which disclosed that $69 million in prepayments had been due by the end of 2015 and not the first quarter of 2016, as Natus Medical Inc. had represented, and revealed that the Supply Contract was governed solely by Venezuelan law, meaning the Venezuelan government could unilaterally renege on all aspects of the agreement. On April 4, 2016, Natus Medical Inc. announced its preliminary revenue for the quarter ended March 31, 2016. The CEO of Natus Medical Inc. announced that due to, "pushouts of key orders in both our international and domestic markets, revenue for the first quarter of 2016 is now weaker than expected." Those who purchased Natus Medical Inc (NASDAQ: BABY) shares should contact the Shareholders Foundation, Inc. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.


News Article | May 8, 2017
Site: www.prlog.org

-- Global brain monitoring market is expected to reach USD 2.0 billion by 2024 from USD 1.2 billion in 2016, at a CAGR of 7.1% in the forecast period 2017 to 2024.The global radiotherapy market is segmented based on therapy, product, application and geography.·         EEG·         TCD·         MEG·         MRI·         CT·         PET·         EMG·         Internal beam radiotherapy·         Systemic radiation therapy·         Traumatic Brain Injury (TBI)·         Headache, dementia·         Epilepsy·         ParkinsonBased on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world.·         Nihon Kohden Corporation·         Philips Healthcare, Metronic PLC·         GE Healthcare, Siemens Healthcare·         Natus Medical Incorporated, Compumedics Limited·         Electrical Geodesics, Inc. CAS Medical Systems Inc·         Advanced Brain Monitoring·         B. Braun Medical, Becton·         Dickinson & Company·         DePuySynthes Companies·         Cadwell Industries, Inc·         Masimo Corporation·         Elekta AB (pub)·         Integra LifeSciences Corporation·         Rimed Inc.·         Yokogawa Electric Corporation·         EMOTIV Inc.and Neural AnalyticsReport Access: http://databridgemarketresearch.com/ reports/global- radiot... Data Bridge Market Research4th Floor, Mega Center,Magarpatta City, Pune – 411028Tel: +1-888-387-2818Email: Sales@databridgemarketresearch.comVisit Data Bridge Blog@ http://databridgemarketresearch.com/blog/LinkedIn: https://www.linkedin.com/company/data-bridge-market-research


News Article | May 8, 2017
Site: www.prnewswire.com

·         Sleep aids are drugs and devices that are used to diagnose and treat sleep disorders, such as sleep apnea and insomnia. ·         Sleep disorders are caused due to substance misuse, stressful work environment, and inconsistent sleep pattern. ·         The global sleep aids market was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2022, registering a CAGR of 7.0% from 2017 to 2023. ·         The global sleep aids market is segmented based on product, sleep disorder, and geography. ·         The market growth is attributed to the surge in prevalence of sleep disorders, rise in geriatric and obese population, and change in lifestyle. Sleep Aids Market by Product (Mattress & Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices) and Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking, and Other Sleep Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2023 Sleep aids are drugs and devices that are used to diagnose and treat sleep disorders, such as sleep apnea and insomnia. Sleep disorders are caused due to substance misuse, stressful work environment, and inconsistent sleep pattern. Sleep aids help to improve the quality of sleep by reducing the time required to fall asleep and increasing the duration of quality sleep. The global sleep aids market was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2022, registering a CAGR of 7.0% from 2017 to 2023. The global sleep aids market is segmented based on product, sleep disorder, and geography. Based on product, it is categorized into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medications segment is further divided into prescription-based drugs, over-the-counter (OTC) drugs, and herbal drugs. Based on sleep disorder, it is classified into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorder. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The market growth is attributed to the surge in prevalence of sleep disorders, rise in geriatric and obese population, and change in lifestyle. The surge in disposable income; increase in awareness about sleep disorders; stressful work issues; enhanced intake of caffeine, tobacco, and alcohol; and technological advancements are expected to boost the sleep aids market growth. However, adverse effects of sleep aids medication in patient with sleep disorders, such as dizziness, diarrhea, constipation, daytime drowsiness; and expiration on sleep drugs patents are expected to hamper the market growth. KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities. Market estimations provided are based on comprehensive analysis of the key developments in the industry. The global market is comprehensively analyzed with respect to product, sleep disorder, and geography. In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning. The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market. KEY PLAYERS PROFILED Koninklijke Philips N.V. Merck & Co. Sanofi DeVilbiss Healthcare LLC. Pfizer Inc. SleepMed Inc. Cadwell Laboratories Inc. Compumedics Limited Natus Medical Incorporated GlaxoSmithKline plc. Sleep Aids Market Key Segments BY PRODUCT Mattresses & Pillows Sleep Laboratories Medications Prescription-based drugs OTC drugs Herbal drugs Sleep Apnea Devices BY SLEEP DISORDER Insomnia Sleep Apnea Restless Legs Syndrome Narcolepsy Sleep Walking Other Sleep Disorders BY GEOGRAPHY North America U.S. Canada Mexico Europe Germany UK France Spain Rest of Europe Asia-Pacific Japan China Australia India Rest of Asia-Pacific LAMEA Brazil Turkey Republic of South Africa Saudi Arabia Read the full report: http://www.reportlinker.com/p04883729/Sleep-Aids-Market-Global-Opportunity-Analysis-and-Industry-Forecast.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sleep-aids-market-is-estimated-to-reach-79851-million-by-2022-300453104.html


Patent
Natus Medical | Date: 2017-08-30

A method and apparatus for determining the impedance of the plurality of channels comprising a plurality of channels having a plurality of first channels and a plurality of second channels, at least one reference channel, a signal generator electrically connected to the plurality of channels, a reference signal generator connected to the reference channel, at least one amplifier connected to each of the plurality of channels and the reference channel and at least one filter connected to an output of the at least one amplifier to filter the output signal from the at least one amplifier. The signal generator is configured to provide a plurality of input signals to the plurality of channels. The reference signal generator provides an input signal to the reference channel.


News Article | September 11, 2017
Site: globenewswire.com

PLEASANTON, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) --  Natus Medical Incorporated (NASDAQ:BABY) today announced that it has entered into a definitive agreement with Integra LifeSciences Holdings Corporation (NASDAQ:IART) under which Natus will acquire certain neurosurgery business assets from Integra LifeSciences in an all cash transaction for $47.5 million.  With current annual revenue of approximately $50 million, the acquisition marks Natus' entry into the $2 billion global neurosurgery market. The divestiture by Integra is contingent on the consummation of Integra's proposed acquisition of Codman Neurosurgery. As part of the transaction, Natus will acquire the global Camino ICP monitoring product line, including its San Diego manufacturing facility, from Integra. The sale also includes the U.S. rights relating to Integra's fixed pressure shunts, as well as U.S. rights to Codman's DURAFORM® dural graft implant, standard EVD catheters and CSF collection systems. The market leading Camino® intracranial pressure monitoring system (ICP), is a modernized platform designed to incorporate both tunneled and bolted advanced monitoring technologies, which monitor ICP in either the parenchyma or ventricular space via proprietary catheters. "This acquisition expands Natus' market leading neurodiagnostic business into the adjacent neurosurgery market," said Jim Hawkins, President and Chief Executive Officer of Natus. "We expect this acquisition to be immediately accretive to earnings with gross and operating margins similar to our consolidated margins." Integra is divesting these assets in connection with the review by the Federal Trade Commission ("FTC") of Integra's proposed acquisition of Johnson & Johnson's Codman Neurosurgery assets. Both the divestiture and the pending acquisition of Codman Neurosurgery remain subject to final regulatory approvals and satisfaction of other customary closing conditions. Both transactions are expected to close in October 2017 after securing regulatory clearance. Natus will use cash on hand and available from its credit facility to fund the acquisition. Natus is a leading provider of healthcare products and services used in the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Additional information about Natus Medical can be found at . Non-GAAP earnings related to the acquisition and ongoing performance of the neurosurgery assets will exclude direct acquisition costs, amortization of purchased intangibles and the cost acquired profit in inventory. A reconciliation between GAAP and non-GAAP financial measures can be found in our quarterly financial reports where actual results are presented. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding revenue and profitability expectations of the neurosurgery assets acquisition, its anticipated close date and obtaining required regulatory approvals to complete the transaction. These statements relate to current estimates and assumptions of our management as of the date of this press release, and future events or Natus' future financial performance or results, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the ability to consummate the acquisition of the neurosurgery assets and the ability to successfully integrate the business, the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement. More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2016, and its subsequent quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.


Patent
Natus Medical | Date: 2012-07-09

The described embodiments relate generally to methods, systems and devices for sleep stage determination using frontal electrodes. Certain embodiments relate to a system for sleep stage determination comprising a sensing unit and a processing unit. The sensing unit is positioned over a forehead area of a patient and has first, second and third electrodes for positioning at locations on or adjacent the forehead area for detecting electrical potentials of a human head. The processing unit is coupled to the sensing unit for receiving biological signals corresponding to the detected electrical potentials and processing the biological signals to determine a sleep stage of the patient. The processing of the biological signals is based on a plurality of rules.


Patent
Natus Medical | Date: 2014-10-22

A method and apparatus for determining the impedance of the plurality of channels comprising a plurality of channels having a plurality of first channels and a plurality of second channels, at least one reference channel, a signal generator electrically connected to the plurality of channels, a reference signal generator connected to the reference channel, at least one amplifier connected to each of the plurality of channels and the reference channel and at least one filter connected to an output of the at least one amplifier to filter the output signal from the at least one amplifier. The signal generator is configured to provide a plurality of input signals to the plurality of channels. The reference signal generator provides an input signal to the reference channel.

Loading Natus Medical collaborators
Loading Natus Medical collaborators